The results showed that by days 6 and 10 post-treatment, only NV1042-inoculated tumors contained CD8+ and CD4+ cells, demonstrating superior anti-tumor immunity, while NV1042-treated tumors showed a significant reduction in CD31 staining, implying an effective anti-angiogenic effect of IL-12 [218]. The gene discussed is CD8A; the disease is neoplasm.